Prothena Corporation

Prothena Corporation EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Prothena Corporation (PRTA) as of Oct 10, 2026 is -2.49. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.97 — a change of -16.25% (higher).

EV/EBIT

-2.49

YoY

-16.25%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Prothena Corporation is 2025 -2.49 . EV/EBIT (Enterprise Value to EBIT) of Prothena Corporation was 2024 -2.97 . It decreases by -16.25% higher compared to the previous year.

The Prothena Corporation EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-5.36 USD
Jan 1, 2020
-4.08 USD
Jan 1, 2021
6.39 USD
Jan 1, 2022
-3.49 USD
Jan 1, 2023
-2.41 USD
Jan 1, 2024
-2.97 USD
Jan 1, 2025
-2.49 USD
Jan 1, 2026 (e)
347.19 USD
The Prothena Corporation EV/EBIT history
YEAREV/EBITYoY
est347.19-14,037.94%
-2.49-16.25%
-2.97+23.60%
-2.41-31.13%
-3.49-154.71%
6.39-256.63%
-4.08-23.98%
-5.36+85.37%
-2.89-0.88%
-2.92+1.32%
-2.88-49.89%
-5.75-91.68%
-69.14+1,478.61%
-4.38+434.15%
-0.82—
Access this data via the Eulerpool API

Prothena Corporation Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Prothena Corporation's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Prothena Corporation's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Prothena Corporation's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Prothena Corporation grows earnings faster than its peers.

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prothena Corporation stock

EV/EBIT (Enterprise Value to EBIT) of Prothena Corporation is -2.49 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Prothena Corporation changed from -2.97 to -2.49, representing a -16.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Prothena Corporation with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Prothena Corporation

All Key Metrics — Prothena Corporation